KemPharm, which is developing abuse-deterrent versions of widely-prescribed pain medications, announced terms for its IPO on Friday.
The Coralville, IA-based company plans to raise $52 million by offering 4 million shares at a price range of $12 to $14. At the midpoint of the proposed range, KemPharm would command a fully diluted market value of $207 million.
Help employers...
The Coralville, IA-based company plans to raise $52 million by offering 4 million shares at a price range of $12 to $14. At the midpoint of the proposed range, KemPharm would command a fully diluted market value of $207 million.
Help employers...
